Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.58 USD | -0.52% | -1.44% | +5.12% |
Financials (USD)
Sales 2024 * | 80.45M | Sales 2025 * | 38.54M | Capitalization | 1.44B |
---|---|---|---|---|---|
Net income 2024 * | -485M | Net income 2025 * | -579M | EV / Sales 2024 * | 9.21 x |
Net cash position 2024 * | 698M | Net cash position 2025 * | 766M | EV / Sales 2025 * | 17.5 x |
P/E ratio 2024 * |
-2.97
x | P/E ratio 2025 * |
-2.69
x | Employees | 587 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 88.3% |
Latest transcript on Vir Biotechnology, Inc.
1 day | -0.52% | ||
1 week | -1.44% | ||
Current month | +2.97% | ||
1 month | +1.78% | ||
3 months | -5.50% | ||
6 months | +10.50% | ||
Current year | +5.12% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 55 | - | |
Sung Lee
DFI | Director of Finance/CFO | 53 | 23-03-26 |
Jennifer Towne
CTO | Chief Tech/Sci/R&D Officer | - | Nov. 05 |
Members of the board | Title | Age | Since |
---|---|---|---|
Charles Sigal
BRD | Director/Board Member | 72 | 20-07-01 |
Robert Perez
BRD | Director/Board Member | 59 | 16-12-31 |
Robert More
BRD | Director/Board Member | 56 | 16-08-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
12.90% | 254 M€ | +14.16% | - | |
0.63% | 28 M€ | -2.99% | ||
0.58% | 25 M€ | -4.18% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-06-04 | 10.58 | -0.47% | 746,949 |
24-06-03 | 10.63 | +3.51% | 982,795 |
24-05-31 | 10.27 | -1.15% | 971,027 |
24-05-30 | 10.39 | +2.87% | 924,219 |
24-05-29 | 10.1 | -5.87% | 735,818 |
Delayed Quote Nasdaq, June 04, 2024 at 03:59 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+5.12% | 1.45B | |
+46.19% | 56.65B | |
-6.14% | 39.44B | |
+39.19% | 39.03B | |
-6.65% | 26.86B | |
+12.33% | 26.75B | |
-21.78% | 19.03B | |
-0.35% | 12.28B | |
+24.18% | 12.26B | |
+28.38% | 12.04B |
- Stock Market
- Equities
- VIR Stock